175 Innovation Boulevard
Wilmington, DE 19805
United States
302 467 1280
https://preludetx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 128
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director | 905.92k | N/D | 1966 |
Dr. Edna Huang M.D. | President & Chief Medical Officer | 865.63k | N/D | 1973 |
Lindsey Trickett | Vice President of Investor Relations | N/D | N/D | N/D |
Ms. Michele Porreca M.B.A. | Chief People Officer | N/D | N/D | N/D |
Dr. Andrew P. Combs Ph.D. | Executive VP & Chief Chemistry Officer | 562.46k | N/D | 1967 |
Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine | N/D | N/D | N/D |
Dr. William B. Novotny M.D. | Senior Vice President of Clinical Development | N/D | N/D | N/D |
Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development | N/D | N/D | 1979 |
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
La calificación ISS Governance QuickScore de Prelude Therapeutics Incorporated a partir del 29 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 2; Junta: 5; Derechos del accionista: 10; Compensación: 9.